Rivaroxaban
Brand names: Xarelto
Part of: Blood thinners
At a glance
- Medicare prescriptions, 2024
- 5,814,081
- Medicare drug cost
- $5.37B
- Average cost per prescription
- $923
- Clinicians who prescribed it
- 132,450
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation for treatment of deep vein thrombosis (DVT) for treatment of pulmonary embolism (PE) for reduction in the risk of recurrence of DVT or PE for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA A. Premature discontinuation of XARELTO increases the risk of thrombotic events Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. B. Spinal/epidural hematoma Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Cardiology 20.4%
- Family Medicine 19.8%
- Internal Medicine 19.3%
- Nurse Practitioners 14.5%
- Interventional Cardiology 6.9%
- Physician Assistants 5.1%
- Cardiac Electrophysiology 3.9%
- Hematology & Oncology 2.4%
- Geriatric Medicine 1.6%
- General Practice 1.1%
- Vascular Surgery 0.8%
- Medical Oncology 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 5% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +43%
- Minnesota +36%
- Iowa +30%
- South Dakota +28%
- Hawaii +27%
- Rhode Island (smallest change) −9%
- California (smallest change) −5%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Apotex Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 6 mm | R 2PT5 |
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | red round tablet, 6 mm | 10 XA |
| 15 mg | red round tablet, 6 mm | 15 XA |
| 20 mg | red triangle tablet, 7 mm | 20 XA |
Janssen Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 6 mm | 2 5 XA |
| 10 mg | red round tablet, 6 mm | 10 XA |
| 15 mg | red round tablet, 6 mm | 15 XA |
| 20 mg | red triangle tablet, 7 mm | 20 XA |
| 155 mg | white granule | |
Lifestar Pharma LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 10 mm | LS 6 |
Micro Labs Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 5 mm | 2 5 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $20,882 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Janssen Scientific Affairs, LLC $18,400
- Janssen Pharmaceuticals, Inc $2,019
- Janssen Biotech, Inc. $388
- Biosense Webster, Inc. $75
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.